Publications by authors named "Z Miltenyi"
The overall- and progression-free survival rates of Hodgkin's lymphoma patients have improved. Our goal was to examine the changes in our treatment results and their causes depending on the daily diagnostic and therapeutic practice. We analysed data of 776 classical Hodgkin lymphoma patients treated between 1980 and 2019.
View Article and Find Full Text PDFObjective Non-Hodgkin lymphoma (NHL) arising as a secondary malignancy in patients treated for classical Hodgkin lymphoma (cHL) is an infrequent and challenging clinical scenario. NHL can be presented synchronously with cHL or may develop later, sequentially, up to years after treatment for cHL. The relationship between the two lymphomas is unclear, and there are no clear guidelines for the management of these patients.
View Article and Find Full Text PDFArticle Synopsis
- * AEL is characterized by specific genetic changes, including multi-allelic mutations, and can develop after treatments like chemotherapy and stem cell transplants, as seen in two case studies.
- * Several potential mechanisms for AEL's development post-treatment are proposed, including the presence of abnormal stem cells, survival of mutated cells after chemotherapy, and new mutations arising from treatment-related complications.
Aims: TP53 alterations have a significant prognostic effect in myeloid neoplasms. Our objective was to investigate the TP53 gene mutation status, p53 protein expression and their relationship in dysplasia-related myeloid neoplasms with varying levels of myeloblast counts.
Methods And Results: A total of 76 bone marrow biopsy samples with different blast counts were analysed.
Autologous stem cell transplantation (ASCT) is the standard treatment of primary refractory or relapsed Hodgkin-lymphoma, which can provide a cure rate of about 50%. The aim of our study was to analyze the data of 126 HL patients undergoing AHSCT in Hungary between 01/01/2016 and 31/12/2020. We assessed the progression-free and overall survival, the prognostic role of PET/CT performed before transplantation and effect of brentuximab vedotin (BV) treatment on survival outcomes.
View Article and Find Full Text PDF